IRS Plans a Full-Year Pass on 280E for Medical Marijuana

Key Takeaways

• IRS grants full‑year deductions for qualifying medical marijuana businesses.
• Only FDA‑approved and state‑licensed medical products move to Schedule III.
• Recreational and bulk cannabis remain Schedule I, keeping 280E penalties.
• Operators must apportion overhead between medical and recreational lines.
• Effective tax rate could drop below 70% for eligible medical firms.

Pulse Analysis

Section 280E has long been the tax Achilles’ heel for the cannabis industry, forcing growers and dispensaries to pay federal taxes on gross revenue rather than profit. By barring deductions for expenses such as payroll, rent and advertising, many operators have reported effective tax rates that exceed 70 percent. The recent DOJ Final Order that moves FDA‑approved marijuana drugs and state‑licensed medical products to Schedule III creates a narrow but meaningful opening for tax relief, but only for businesses that meet strict medical‑only criteria.

The IRS’s forthcoming guidance clarifies that the rescheduling will apply to the entire 2026 taxable year, allowing qualifying medical operators to claim ordinary deductions for the full period. This eliminates the previously anticipated mid‑year bifurcation and represents the most generous relief the agency has offered. However, firms that operate dual‑license models—selling both medical and adult‑use cannabis—must now meticulously apportion shared costs like utilities, rent and administrative salaries between the two categories, a process that will likely increase compliance overhead.

For the broader market, the impact is mixed. While medical‑only growers and dispensaries can expect a noticeable reduction in their effective tax burden, the recreational segment remains firmly under Schedule I, meaning 280E continues to apply. Investors and operators will need to reassess business models, potentially focusing more on medical product pipelines or seeking efficiencies in the recreational side to mitigate the tax disparity. The policy shift underscores the fragmented regulatory landscape and signals that future tax reforms may continue to differentiate between medical and adult‑use cannabis activities.